DOCSLIB.ORG

Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients Article Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients | Sunil V. Badve,*†‡ Elaine M. Pascoe,* Michael Burke,§ Philip A. Clayton, ¶ Scott B. Campbell,§ Carmel M. Hawley,*§ | Wai H. Lim,** Stephen P. McDonald, ¶ Germaine Wong,†† and David W. Johnson*§ Abstract Background and objectives Emerging evidence from recently published observational studies and an individual – *Australasian Kidney patient data meta analysis shows that mammalian target of rapamycin inhibitor use in kidney transplantation Trials Network, School is associated with increased mortality. Therefore, all-cause mortality and allograft loss were compared of Medicine, between use and nonuse of mammalian target of rapamycin inhibitors in patients from Australia and New University of Zealand, where mammalian target of rapamycin inhibitor use has been greater because of heightened skin Queensland, cancer risk. Brisbane, Australia; †Department of Nephrology, Design, setting, participants, & measurements Our longitudinal cohort study included 9353 adult patients who St. George Hospital, underwent 9558 kidney transplants between January 1, 1996 and December 31, 2012 and had allograft survival Sydney, Australia; ‡ $1 year. Risk factors for all-cause death and all–cause and death–censored allograft loss were analyzed by Renal and Metabolic Division, The George multivariable Cox regression using mammalian target of rapamycin inhibitor as a time-varying covariate. fi Institute for Global Additional analyses evaluated mammalian target of rapamycin inhibitor use at xed time points of baseline and Health, Sydney, 1year. Australia; §Department of Results Patients using mammalian target of rapamycin inhibitors were more likely to be white and have a history Nephrology, Princess Alexandra Hospital, of pretransplant cancer. Over a median follow-up of 7 years, 1416 (15%) patients died, and 2268 (24%) allografts Brisbane, Australia; | were lost. There was a higher risk of all-cause mortality with time–varying mammalian target of rapamycin The Australia and inhibitor use (hazard ratio, 1.47; 95% confidence interval, 1.23 to 1.76) as well as in the fixed time model analyses New Zealand Dialysis comparing mammalian target of rapamycin inhibitor use at baseline (hazard ratio, 1.54; 95% confidence interval, and Transplant fi – Registry, Adelaide, 1.22 to 1.93) and 1 year (hazard ratio, 1.63; 95% con dence interval, 1.32 to 2.01). Time varying mammalian target Australia; ¶Central of rapamycin inhibitor use was associated with higher risk of death because of malignancy (hazard ratio, 1.37; Northern Adelaide 95% confidence interval, 1.09 to 1.71). There were no statistically significant differences in the risk of all–cause Renal and (hazard ratio, 0.98; 95% confidence interval, 0.85 to 1.12) and death–censored (hazard ratio, 0.85; 95% confidence Transplantation interval, 0.69 to 1.03) allograft loss between the mammalian target of rapamycin inhibitor use and nonuse groups Service, School of fi Medicine, University in the time-varying model as well as the xed time models. of Adelaide, Adelaide, Australia; Conclusions Mammalian target of rapamycin inhibitor use was associated with a higher risk of all-cause mortality **Department of but not allograft loss. Renal Medicine, Sir Clin J Am Soc Nephrol – Charles Gairdner 11: 1845 1855, 2016. doi: 10.2215/CJN.00190116 Hospital, Perth, Australia; and ††Center for Kidney Research, The Introduction nonskin cancer malignancies after kidney transplanta- Children’s Hospital at Mammalian target of rapamycin (mTOR) inhibitors tion (1,6,7). A Scientific Registry of Renal Transplant Westmead, Sydney, sirolimus and everolimus are commonly prescribed Recipients (SRTR) study reported significantly higher Australia maintenance immunosuppressive agents in kidney risks of death and graft loss with sirolimus versus transplantation. Randomized trials with short–term tacrolimus use (8). Subsequently, a Hungarian study Correspondence: follow-up have shown that de novo or delayed intro- Dr. Sunil V. Badve, reported a higher mortality risk with mTOR inhibitor Department of duction of mTOR inhibitors with and without calci- use (9). A United Network for Organ Sharing (UNOS) Nephrology, The neurin inhibitors is associated with increased risks of study also reported higher risks of death and graft St. George Hospital, rejection, hyperlipidemia, proteinuria, and delayed loss with mTOR inhibitor versus calcineurin inhibitor Suite 1, 50 wound healing. Compared with calcineurin inhibi- use (10). More recently, an individual patient data Montgomery Street, – Kogarah, New South tors, mTOR inhibitors have been shown to achieve meta analysis using data from 21 randomized trials Wales 2217, Australia. superior allograft function up to 5 years after trans- showed that sirolimus was associated with a 43% Email: sbadve@ plantation and are associated with reduced risks of higher risk of all-cause death compared with in con- georgeinstitute.org.au cytomegalovirusandBKvirusinfections(1–5). trols (7). mTOR inhibitors have been shown to reduce the Because of heightened skin cancer risk, the use of risk of nonmelanoma skin cancers (NMSCs) and mTOR inhibitors is greater in Australia than in the www.cjasn.org Vol 11 October, 2016 Copyright © 2016 by the American Society of Nephrology 1845 1846 Clinical Journal of the American Society of Nephrology United States (11,12). Therefore, the aim of this study was validation are described in detail on the ANZDATA Reg- to compare all–cause patient mortality and all–cause and istry website (http://www.anzdata.org.au). The data col- death–censored allograft loss in kidney transplant recipi- lected include demographic details; comorbidities; history ents treated with or without mTOR inhibitors using data of pretransplant cancer; donor- and transplant-related from the Australia and New Zealand Dialysis and Trans- characteristics; the number, type, and treatment of rejec- plant (ANZDATA) Registry. tion episodes; nonskin tumors; melanomas; and skin tu- mors. The information about immunosuppressive Materials and Methods medications and serum creatinine is collected at 1, 2, 3, and6months;1,2,3,5,7,and10yearsaftertransplant Study Population The study included a total of 9353 adult patients with surgery; and every 5 years thereafter. Exact start and end ESRD who underwent 9558 living and deceased donor dates of immunosuppressive medications and blood drug kidney transplants in Australia and New Zealand between concentrations are not collected. Information on how the January 1, 1996 and December 31, 2012 whose allograft causes of death and graft loss are categorized by the ANZ- survived at least 1 year. Patients were excluded if they were DATA Registry is described in Supplemental Table 1. younger than 18 years old at transplantation, were multi- organ transplant recipients, or had received their first Study Outcomes kidney transplant before January 1, 1996. The primary study outcomes were all-cause mortality and all–cause allograft loss. Secondary study outcomes Data Collection were death with functioning graft, death after graft loss, – fi The ANZDATA Registry collects data in accordance with death censored allograft loss, cause-speci c mortality, and – fi the Australian Commonwealth Privacy Act and associated cause speci c allograft loss. All analyses, except death state legislation governing health data collection, and with functioning graft and death after graft loss, included fi individual opt–in patient consent is not required for the rst as well as repeat kidney transplants. registry data. This analysis was performed on an anonymized extract released by the registry to researchers. The clinical Statistical Analyses and research activities being reported are consistent with For the purpose of describing the baseline characteristics, the Principles of the Declaration of Istanbul as outlined in the study population was divided into four groups: (1) the Declaration of Istanbul on Organ Trafficking and never treated with mTOR inhibitor (never used group), Transplant Tourism. The methods of data collection and (2) treated with mTOR inhibitor–based immunosuppressive Table 1. Baseline patient characteristics by mammalian target of rapamycin inhibitor use Early Late Variable Never Used Baseline Use Total P Value Conversion Conversion N 7801 481 504 567 9353 Men 4820 (62) 315 (65) 315 (63) 379 (67) 5829 (62) 0.05 Age, yr, mean6SD 47.1613.2 44.9612.4 48.6612.8 45.9613.1 47613.1 ,0.001 Ethnicity ,0.001 White 6295 (81) 437 (91) 429 (85) 486 (86) 7647 (82) ATSI 234 (3) 5 (1) 18 (4) 15 (3) 272 (3) Maori/PI 403 (5) 1 (,1) 8 (2) 9 (2) 421 (5) Asian 451 (6) 22 (5) 31 (6) 33 (6) 537 (6) Other 418 (5) 16 (3) 18 (4) 24 (4) 476 (5) Primary cause of ESRDa 0.004 Chronic glomerulopathy 3741 (48) 247 (51) 265 (53) 271 (48) 4524 (48) Diabetic nephropathy 758 (10) 29 (6) 31 (6) 34 (6) 852 (9) Renovascular disease 456 (6) 29 (6) 25 (5) 31 (5) 541 (6) Polycystic kidney disease 1203 (15) 88 (18) 88 (17) 89 (16) 1468 (16) Reflux or obstructive 863 (11) 55 (11) 47 (9) 74 (13) 1039 (11) nephropathy Other 441 (6) 21 (4) 29 (6) 41 (7) 532 (6) Unknown 333 (4) 12 (2) 19 (4) 27 (5) 391 (4) Comorbid conditiona Current or former smoker 3379 (44) 211 (44) 229 (46) 234 (41) 4053 (44) 0.50 Chronic lung disease 355 (5) 24 (5) 23 (5) 24 (4) 426 (5) 0.90 Cardiovascular disease 1148 (15) 50 (10) 64 (13) 62 (11) 1324 (14) 0.004 Diabetes mellitus 1026 (13) 46 (10) 58 (12) 46 (8) 1176 (13) 0.001 Cancer 2298 (29) 185 (38) 147 (29) 261 (46) 2891 (31) ,0.001 All
Load more

Recommended publications
  • The Application of a Characterized Pre-Clinical
    THE APPLICATION OF A CHARACTERIZED PRE-CLINICAL GLIOBLASTOMA ONCOSPHERE MODEL TO IN VITRO AND IN VIVO THERAPEUTIC TESTING by Kelli M. Wilson A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland March, 2014 ABSTRACT Glioblastoma multiforme (GBM) is a lethal brain cancer with a median survival time (MST) of approximately 15 months following treatment. A serious challenge facing the development of new drugs for the treatment of GBM is that preclinical models fail to replicate the human GBM phenotype. Here we report the Johns Hopkins Oncosphere Panel (JHOP), a panel of GBM oncosphere cell lines. These cell lines were validated by their ability to form tumors intracranially with histological features of human GBM and GBM variant tumors. We then completed whole exome sequencing on JHOP and found that they contain genetic alterations in GBM driver genes such as PTEN, TP53 and CDKN2A. Two JHOP cell lines were utilized in a high throughput drug screen of 466 compounds that were selected to represent late stage clinical development and a wide range of mechanisms. Drugs that were inhibitory in both cell lines were EGFR inhibitors, NF-kB inhibitors and apoptosis activators. We also examined drugs that were inhibitory in a single cell line. Effective drugs in the PTEN null and NF1 wild type cell line showed a limited number of drug targets with EGFR inhibitors being the largest group of cytotoxic compounds. However, in the PTEN mutant, NF1 null cell line, VEGFR/PDGFR inhibitors and dual PIK3/mTOR inhibitors were the most common effective compounds.
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 31, No. 3, 2017 WHO Drug Information Contents Medicines regulation 420 Post-market monitoring EMA platform gains trade mark; Automated 387 Regulatory systems in India FDA field alert reports 421 GMP compliance Indian manufacturers to submit self- WHO prequalification certification 421 Collaboration 402 Prequalification process quality China Food and Drug Administration improvement initiatives: 2010–2016 joins ICH; U.S.-EU cooperation in inspections; IGDRP, IPRF initiatives to join 422 Medicines labels Safety news Improved labelling in Australia 423 Under discussion 409 Safety warnings 425 Approved Brimonidine gel ; Lactose-containing L-glutamine ; Betrixaban ; C1 esterase injectable methylprednisolone inhibitor (human) ; Meropenem and ; Amoxicillin; Azithromycin ; Fluconazole, vaborbactam ; Delafloxacin ; Glecaprevir fosfluconazole ; DAAs and warfarin and pibrentasvir ; Sofosbuvir, velpatasvir ; Bendamustine ; Nivolumab ; Nivolumab, and voxilaprevir ; Cladribine ; Daunorubicin pembrolizumab ; Atezolizumab ; Ibrutinib and cytarabine ; Gemtuzumab ozogamicin ; Daclizumab ; Loxoprofen topical ; Enasidenib ; Neratinib ; Tivozanib ; preparations ; Denosumab ; Gabapentin Guselkumab ; Benznidazole ; Ciclosporin ; Hydroxocobalamine antidote kit paediatric eye drops ; Lutetium oxodotreotide 414 Diagnostics Gene cell therapy Hightop HIV home testing kits Tisagenlecleucel 414 Known risks Biosimilars Warfarin ; Local corticosteroids Bevacizumab; Adalimumab ; Hydroquinone skin lighteners Early access 415 Review outcomes Idebenone
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    Confidential Clinical study protocol number: J1228 Page 1 Version Date: May 7, 2018 IRB study Number: NA_00067315 A Trial of maintenance Rituximab with mTor inhibition after High-dose Consolidative Therapy in CD20+, B-cell Lymphomas, Gray Zone Lymphoma, and Hodgkin’s Lymphoma Principal Investigator: Douglas E. Gladstone, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1650 Orleans Street, CRBI-287 Baltimore, MD 21287 Phone: 410-955-8781 Fax: 410-614-1005 Email: [email protected] IRB Protocol Number: NA_00067315 Study Number: J1228 IND Number: EXEMPT Novartis Protocol Number: CRAD001NUS157T Version: May 7, 2018 Co-Investigators: Jonathan Powell 1650 Orleans Street, CRBI-443 Phone: 410-502-7887 Fax: 443-287-4653 Email: [email protected] Richard Jones 1650 Orleans Street, CRBI-244 Phone: 410-955-2006 Fax: 410-614-7279 Email: [email protected] Confidential Clinical study protocol number: J1228 Page 2 Version Date: May 7, 2018 IRB study Number: NA_00067315 Satish Shanbhag Johns Hopkins Bayview Medical Center 301 Building, Suite 4500 4940 Eastern Ave Phone: 410-550-4061 Fax: 410-550-5445 Email: [email protected] Statisticians: Gary Rosner Phone: 410-955-4884 Email: [email protected] Marianna Zahurak Phone: 410-955-4219 Email: [email protected] Confidential Clinical study protocol number: J1228 Page 3 Version Date: May 7, 2018 IRB study Number: NA_00067315 Table of contents Table of contents ......................................................................................................................... 3 List of abbreviations
    [Show full text]
  • Weak Interaction of the Antimetabolite Drug Methotrexate with a Cavitand Derivative
    International Journal of Molecular Sciences Article Weak Interaction of the Antimetabolite Drug Methotrexate with a Cavitand Derivative Zsolt Preisz 1,2, Zoltán Nagymihály 3,4, Beáta Lemli 1,4 ,László Kollár 3,4 and Sándor Kunsági-Máté 1,2,4,* 1 Institute of Organic and Medicinal Chemistry, Medical School, University of Pécs, Szigeti 12, H-7624 Pécs, Hungary; [email protected] (Z.P.); [email protected] (B.L.) 2 Department of General and Physical Chemistry, Faculty of Sciences, University of Pécs, Ifjúság 6, H 7624 Pécs, Hungary 3 Department of Inorganic Chemistry, Faculty of Sciences, University of Pécs, Ifjúság 6, H 7624 Pécs, Hungary; [email protected] (Z.N.); [email protected] (L.K.) 4 János Szentágothai Research Center, University of Pécs, Ifjúság 20, H-7624 Pécs, Hungary * Correspondence: [email protected]; Tel.: +36-72-503600 (ext. 35449) Received: 2 June 2020; Accepted: 16 June 2020; Published: 18 June 2020 Abstract: Formation of inclusion complexes involving a cavitand derivative (as host) and an antimetabolite drug, methotrexate (as guest) was investigated by photoluminescence measurements in dimethyl sulfoxide solvent. Molecular modeling performed in gas phase reflects that, due to the structural reasons, the cavitand can include the methotrexate in two forms: either by its opened structure with free androsta-4-en-3-one-17α-ethinyl arms or by the closed form when all the androsta-4-en-3-one-17α-ethinyl arms play role in the complex formation. Experiments reflect enthalpy driven complex formation in higher temperature range while at lower temperature the complexes are stabilized by the entropy gain.
    [Show full text]
  • Public Assessment Report
    Public Assessment Report Tifix 150mg and 500mg film-coated tablets Capecitabine BE/H/195/01-02/DC BE licence no: BE423552-BE423561 Applicant: Alfred E. Tiefenbacher, Germany Date: 27-04-2012 Toepassingsdatum : 15-09-10 Page 1 of 17 Blz. 1 van 17 This assessment report is published by the Federal Agency for Medicines and Health Products following Article 21 (3) and (4) of Directive 2001/83/EC, amended by Directive 2004/27/EC and Article 25 paragraph 4 of Directive 2001/82/EC as amended by 2004/28/EC. The report comments on the registration dossier that was submitted to the Federal Agency for Medicines and Health Products and its fellow organisations in all concerned EU member states. It reflects the scientific conclusion reached by the Federal Agency for Medicines and Health Products and all concerned member states at the end of the evaluation process and provides a summary of the grounds for approval of a marketing authorisation. This report is intended for all those involved with the safe and proper use of the medicinal product, i.e. healthcare professionals, patients and their family and carers. Some knowledge of medicines and diseases is expected of the latter category as the language in this report may be difficult for laymen to understand. This assessment report shall be updated by a following addendum whenever new information becomes available. To the best of the Federal Agency for Medicines and Health Products’ knowledge, this report does not contain any information that should not have been made available to the public. The Marketing Autorisation Holder has checked this report for the absence of any confidential information.
    [Show full text]
  • Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases Combined Or Not with Systemic Chemotherapy
    ANTICANCER RESEARCH 29: 4139-4144 (2009) Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases Combined or Not with Systemic Chemotherapy PIERLUIGI PILATI, ENZO MAMMANO, SIMONE MOCELLIN, EMANUELA TESSARI, MARIO LISE and DONATO NITTI Clinica Chirurgica II, Department of Oncological and Surgical Sciences, University of Padova, 35128 Padova, Italy Abstract. Background: The hypothesis was tested that CRC have liver metastases at autopsy, and the majority of systemic chemotherapy might contribute to improving overall these patients die as a result of their metastatic disease. survival (OS) of patients with unresectable colorectal liver Surgical resection represents the standard treatment of metastases treated with hepatic arterial infusion (HAI). resectable disease and is followed by 5-year overall Patients and Methods: We considered 153 consecutive patients survival (OS) rates of 20% to 40% (2, 3). Unfortunately, retrospectively divided into group A (n=72) treated with HAI only 20% of patients with liver metastases from CRC alone (floxuridine [FUDR] + leucovorin [LV]), and group B present with liver-confined resectable disease and/or are (n=81) treated with HAI combined with systemic candidates for major surgical operation (depending on chemotherapy (5-fluorouracil [5FU] + LV). Results: No comorbidities) (4, 5). significant difference in OS was observed between the two The therapeutic management of unresectable metastases is groups. Median OS was better in patients with <50% of liver more controversial and is generally associated with a dismal involvement (21.3 vs. 13.2 months; p<0.0001) and in prognosis. In fact, despite the improvements achieved with responders vs. non-responders (24.4 vs. 13.4 months; modern systemic chemotherapy (SCT) regimens (e.g.
    [Show full text]
  • Drugs and Life-Threatening Ventricular Arrhythmia Risk: Results from the DARE Study Cohort
    Open Access Research BMJ Open: first published as 10.1136/bmjopen-2017-016627 on 16 October 2017. Downloaded from Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort Abigail L Coughtrie,1,2 Elijah R Behr,3,4 Deborah Layton,1,2 Vanessa Marshall,1 A John Camm,3,4,5 Saad A W Shakir1,2 To cite: Coughtrie AL, Behr ER, ABSTRACT Strengths and limitations of this study Layton D, et al. Drugs and Objectives To establish a unique sample of proarrhythmia life-threatening ventricular cases, determine the characteristics of cases and estimate ► The Drug-induced Arrhythmia Risk Evaluation study arrhythmia risk: results from the the contribution of individual drugs to the incidence of DARE study cohort. BMJ Open has allowed the development of a cohort of cases of proarrhythmia within these cases. 2017;7:e016627. doi:10.1136/ proarrhythmia. Setting Suspected proarrhythmia cases were referred bmjopen-2017-016627 ► These cases have provided crucial safety by cardiologists across England between 2003 and 2011. information, as well as underlying clinical and ► Prepublication history for Information on demography, symptoms, prior medical and genetic data. this paper is available online. drug histories and data from hospital notes were collected. ► Only patients who did not die as a result of the To view these files please visit Participants Two expert cardiologists reviewed data the journal online (http:// dx. doi. proarrhythmia could be included. for 293 referred cases: 130 were included. Inclusion org/ 10. 1136/ bmjopen- 2017- ► Referral of cases by cardiologists alone may have criteria were new onset or exacerbation of pre-existing 016627).
    [Show full text]
  • Recent Topics on the Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 29 May 2019 doi:10.20944/preprints201905.0358.v1 Peer-reviewed version available at Int. J. Mol. Sci. 2019, 20, 3210; doi:10.3390/ijms20133210 1 of 39 1 Review 2 Recent topics on the mechanisms of 3 immunosuppressive therapy-related neurotoxicities 4 Wei Zhang 1, Nobuaki Egashira 1,2,* and Satohiro Masuda 1,2 5 1 Department of Clinical Pharmacology and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, 6 Kyushu University, Fukuoka 812-8582, Japan 7 2 Department of Pharmacy, Kyushu University Hospital, Fukuoka 812-8582, Japan 8 * Correspondence: [email protected], Tel.: 81-92-642-5920 9 Abstract: Although transplantation procedures have been developed for patients with end-stagec 10 hepatic insufficiency or other diseases, allograft rejection still threatens patient health and lifespan. 11 Over the last few decades, the emergence of immunosuppressive agents, such as calcineurin 12 inhibitors (CNIs) and mammalian target of rapamycin (mTOR) inhibitors, have strikingly 13 increased graft survival. Unfortunately, immunosuppressive agent-related neurotoxicity is 14 commonly occurred in clinical situations, with the majority of neurotoxicity cases caused by CNIs. 15 The possible mechanisms whereby CNIs cause neurotoxicity include: increasing the permeability 16 or injury of the blood-brain barrier, alterations of mitochondrial function, and alterations in 17 electrophysiological state. Other immunosuppressants can also induce neuropsychiatric 18 complications. For example, mTOR inhibitors induce seizures; mycophenolate mofetil induces 19 depression and headache; methotrexate affects the central nervous system; mouse monoclonal 20 immunoglobulin G2 antibody against cluster of differentiation 3 also induces headache; and 21 patients using corticosteroids usually experience cognitive alteration.
    [Show full text]
  • Palladium-Mediated Dealkylation of N-Propargyl-Floxuridine As a Bioorthogonal Oxygen-Independent Prodrug Strategy
    OPEN Palladium-Mediated Dealkylation of SUBJECT AREAS: N-Propargyl-Floxuridine as a CHEMOTHERAPY CHEMICAL TOOLS Bioorthogonal Oxygen-Independent DRUG DISCOVERY AND DEVELOPMENT Prodrug Strategy Jason T. Weiss, Neil O. Carragher & Asier Unciti-Broceta Received 2 December 2014 Edinburgh Cancer Research UK Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road Accepted South, Edinburgh EH4 2XR, UK. 26 February 2015 Published 19 March 2015 Herein we report the development and biological screening of a bioorthogonal palladium-labile prodrug of the nucleoside analogue floxuridine, a potent antineoplastic drug used in the clinic to treat advanced cancers. N-propargylation of the N3 position of its uracil ring resulted in a vast reduction of its biological activity (,6,250-fold). Cytotoxic properties were bioorthogonally rescued in cancer cell culture by Correspondence and heterogeneous palladium chemistry both in normoxia and hypoxia. Within the same environment, the requests for materials reported chemo-reversible prodrug exhibited up to 1,450-fold difference of cytotoxicity whether it was in the absence or presence of the extracellular palladium source, underlining the precise modulation of bioactivity should be addressed to enabled by this bioorthogonally-activated prodrug strategy. A.U.-B. (Asier.Unciti- [email protected]. uk) ioorthogonally-activated prodrug therapies are a heterogeneous group of experimentally and clinically- used therapeutic strategies that are founded on a common principle: the site-specific activation of phar- B maceutical substances by the mediation of non-biological, non-perturbing physical or chemical stimuli. While the nature and properties of the triggering stimulus can be manifestly diverse and seemingly unrelated (e.g.
    [Show full text]
  • The Universe of Normal and Cancer Cell Line Responses to Anticancer Treatment: Lessons for Cancer Therapy
    The universe of normal and cancer cell line responses to anticancer treatment: Lessons for cancer therapy Alexei Vazquez Department of Radiation Oncology, The Cancer Institute of New Jersey and UMDNJ-Robert Wood Johnson Medical School. 120 Albany Street, New Brunswick, NJ 08901, USA Abstract According to the Surveillance Epidemiology and End Results report, 1,479,350 men and women will be diagnosed with and 562,340 will die of cancer of all sites in 2009, indicating that about 40% of the cancer patients do not respond well to current anticancer therapies. Using tumor and normal tissue cell lines as a model, we show this high mortality rate is rooted in inherent features of anticancer treatments. We obtain that, while in average anticancer treatments exhibit a two fold higher efficacy when applied to cancer cells, the response distribution of cancer and normal cells significantly overlap. Focusing on specific treatments, we provide evidence indicating that the therapeutic index is proportional to the fraction of cancer cell lines manifesting significantly good responses, and propose the latter as a quantity to identify compounds with best potential for anticancer therapy. We conclude that there is no single treatment targeting all cancer cell lines at a non-toxic dose. However, there are effective treatments for specific cancer cell lines, which, when used in a personalized manner or applied in combination, can target all cancer cell lines. Background a collaboration between The Cancer Genome Project at the Wellcome Trust Sanger Institute Cell culture studies are the starting point of most (UK) and the Center for Molecular Therapeutics screens for anticancer treatments [1, 2].
    [Show full text]
  • August 2019: Methotrexate Mistakes
    August, 2019 www.nursingcenter.com Methotrexate Mistakes Methotrexate is an antimetabolite that interferes with DNA synthesis, repair, and cellular replication. Initially developed as a cancer treatment, methotrexate dosing is based on body surface area and is administered in cycles, rarely daily. The indications for methotrexate expanded to include treatment of rheumatoid arthritis and psoriasis which requires a low dose typically once or twice a week. Because only a few medications are dosed weekly, overdoses have been common, resulting in vomiting, mouth sores, stomatitis, skin lesions, liver failure, renal failure, myelosuppression, gastrointestinal bleeding, pulmonary symptoms, and death. Methotrexate errors have occurred in the following scenarios: • Medication reconciliation and transitions-of-care: missteps happen when patients are admitted to the hospital and upon discharge to home or other healthcare facilities. o Orders may be entered incorrectly into the electronic medical record (EMR). o Errors occur with medication transcription. o Failure to verify the correct indication (cancer versus non-oncologic). o Medications are not reconciled prior to discharge. • Confusing instructions misunderstood by the patient: Methotrexate dosing is complex, often involving titration or escalating weekly doses. This can be very confusing for patients. o For example, an 8-week supply of 2.5 mg tablets (30 tablets) were dispensed with a prescription that read “Take 3 tablets by mouth 1 day for 2 weeks then increase to 4 tablets by mouth 1 day per week thereafter”. The patient erroneously took 3 tablets (7.5 mg) daily for 5 days which caused serious illness. • Look-alike and sound-alike drug names: Methotrexate has been mistaken for metolazone, a diuretic prescribed daily to treat congestive heart failure or kidney disease.
    [Show full text]
  • Gemcitabine Class: Antineoplastic Agent, Antimetabolite (Pyrimidine
    Gemcitabine Class: Antineoplastic Agent, Antimetabolite (Pyrimidine Analog) Indications: Breast cancer Non small cell lung cancer Ovarian cancer Pancreatic cancer Unlabeled use: Bladder cancer Cervical cancer Head and neck cancer Hepatobiliary cancer Hodgkin lymphoma Malignant pleural mesothelioma Non-Hodgkin lymphoma Sarcoma Small cell lung cancer Testicular cancer Unknown-primary, adenocarcinoma Uterine cancer Available dosage form in the hospital: 200 mg VIAL 1gVIAL Trade Names: Gemzar Doses: Details concerning dosing in combination regimens should also be consulted.Note: Prolongation of the infusion duration >60 minutes and administration more frequently than once weekly have been shown to increase toxicity. -Breast cancer, metastatic: I.V.: 1250 mg/m2 over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with paclitaxel) or (unlabeled dosing; as a single agent) 800 mg/m2 over 30 minutes days 1, 8, and 15 of a 28-day treatment cycle (Carmichael, 1995) -Non small cell lung cancer, locally advanced or metastatic: I.V.: 1000 mg/m2 over 30 minutes days 1, 8, and 15; repeat cycle every 28 days (in combination with cisplatin) or 1250 mg/m2 over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with cisplatin) or (unlabeled dosing/combination) 1000 mg/m2 over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with carboplatin) for up to 4 cycles. -Ovarian cancer, advanced: I.V.: 1000 mg/m2 over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with carboplatin) or (unlabeled
    [Show full text]